Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritoma vaccine
- Development stage
- Phase 3
- Lead developer
- Immunomic Therapeutics
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A dendritoma vaccine is a personalized cancer immunotherapy created by fusing autologous dendritic cells (DCs) with autologous tumor cells or tumor lysate. This fusion creates hybrid cells (dendritomas) that efficiently present tumor antigens to the immune system, aiming to stimulate specific T-cell responses against cancer cells. It has been investigated for its potential in treating advanced melanoma and renal cell carcinoma.
- Brand names
- dendritoma vaccine
- Other names
- autologous tumor-dendritic cell fusion vaccinedendritic/tumor cell hybrids
02
Targets
TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on dendritoma vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritoma vaccine.